Antiviral Effects of Interferon-β are Enhanced in the Absence of the Translational Suppressor 4E-BP1 in Myocarditis Induced by Coxsackievirus B3

Rose N.R. , Čiháková D. , Barin J.G. Mechanisms underlying myocarditis. Drug Discov Today Dis Mech 2006; 3: 207–212.

Gupta S. , Markham D.W. , Drazner M.H. , Mammen P.P.A. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 2008; 5: 693–706.

Ellis C.R. , Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev 2007; 15: 170–177.

Liu P.P. , Mason J.W. Advances in the understanding of myocarditis. Circulation 2001; 104: 1076–1082.

Kühl U. , Pauschinger M. , Schwimmbeck P.L. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793–2798.

Bowles N.E. , Ni J. , Kearney D.L. , Pauschinger M. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42: 466–472.

Kim K.S. , Hufnagel G. , Chapman N.M. , Tracy S. The group B coxsackieviruses and myocarditis. Rev Med Virol 2001; 11: 355–368.

Tracy S. , Chapman N.M. , McManus B.M. , Pallansch M.A. , Beck M.A. , Carstens J. A molecular and serologic evaluation of enteroviral involvement in human myocarditis. J Mol Cell Cardiol 1990; 22: 403–414.

Kühl U. , Pauschinger M. , Noutsias M. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘idiopathic’ left ventricular dysfunction. Circulation 2005; 111: 887–893.

Kühl U. , Pauschinger M. , Seeberg B. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112: 1965–1970.

Stewart M.J. , Smoak K. , Blum M.A. , Sherry B. Basal and reovirus-induced beta interferon (IFN-β) and IFN-β-stimulated gene expression are cell type specific in the cardiac protective response. J Virol 2005; 79: 2979–2987.

Zurney J. , Howard K.E. , Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol 2007; 81: 13668–13680.

Richtsteiger R. , Henke-Gendo C. , Schmidtke M. , Harste G. , Heim A. Quantitative multiplex real-time PCR for the sensitive detection of interferon β gene induction and viral suppression of interferon β expression. Cytokine 2003; 24: 190–200.

Kerekatte V. , Keiper B.D. , Badorff C. , Cai A. , Knowlton K.U. , Rhoads R.E. Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff? J Virol 1999; 73: 709–717.

Joachims M. , Van Breugel P.C. , Lloyd R.E. Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J Virol 1999; 73: 718–727.

Sommergruber W. , Ahorn H. , Klump H. 2A proteinases of coxsackie- and rhinovirus cleave peptides derived from elF-4γ via a common recognition motif. Virology 1994; 198: 741–745.

Liebig H.D. , Ziegler E. , Yan R. Purification of two picornaviral 2A proteinases: interaction with eIF-4γ and influence on in vitro translation. Biochemistry 1993; 32: 7581–7588.

Lamphear B.J. , Yan R. , Yang F. Mapping the cleavage site in protein synthesis initiation factor eIF-4γ of the 2A proteases from human coxsackievirus and rhinovirus. J Biol Chem 1993; 268: 19200–19203.

Esfandiarei M. , Luo H. , Yanagawa B. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 2004; 78: 4289–4298.

Cornell C.T. , Kiosses W.B. , Harkins S. , Whitton J.L. Inhibition of protein trafficking by coxsackievirus B3: Multiple viral proteins target a single organelle. J Virol 2006; 80: 6637–6647.

Cornell C.T. , Kiosses W.B. , Harkins S. , Whitton J.L. Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J Virol 2007; 81: 6785–6797.

Dodd D.A. , Giddings T.H.J. , Kirkegaard K. Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection. J Virol 2001; 75: 8158–8165.

Kaur S. , Lal L. , Sassano A. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2007; 282: 1757–1768.

Deonarain R. , Cerullo D. , Fuse K. , Liu P.P. , Fish E.N. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 2004; 110: 3540–3543.

Wang Y.X. , Da Cunha V. , Vincelette J. Antiviral and myocyte protective effects of murine interferon-β and -α2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol Heart Circ Physiol 2007; 293: H69–H76.

Padalko E. , Nuyens D. , De Palma A. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 2004; 48: 267–274.

Matsumori A. , Tomioka N. , Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 1988; 115: 1229–1232.

Borden E.C. , Sen G.C. , Uze G. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6: 975–990.

Parmar S. , Platanias L.C. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15: 431–439.

Lekmine F. , Sassano A. , Uddin S. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 2004; 295: 173–182.

Lekmine F. , Uddin S. , Sassano A. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 2003; 278: 27772–27780.

Guiducci C. , Ghirelli C. , Marloie-Provost M.A. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med 2008; 205: 315–322.

Cao W. , Manicassamy S. , Tang H. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008; 9: 1157–1164.

Schmitz F. , Heit A. , Dreher S. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008; 38: 2981–2992.

Colina R. , Costa-Mattioli M. , Dowling R.J. Translational control of the innate immune response through IRF-7. Nature 2008; 452: 323–328.

Bartlett E.J. , Lenzo J.C. , Sivamoorthy S. , Mansfield J.P. , Cull V.S. , James C.M. Type I IFN-β gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis. Immunol Cell Biol 2004; 82: 119–126.

Henke A. , Huber S. , Stelzner A. , Whitton J.L. The role of CD8⁺ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995; 69: 6720–6728.

Opavsky M.A. , Penninger J. , Aitken K. Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection. Circ Res 1999; 85: 551–558.